- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
FDA denies claims for Zetia, Vytorin
FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
While Zetia and Vytorin are indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia, the effect of Zetia on cardiovascular morbidity and mortality “has not been determined” by FDA, according to a Merck statement.
Related: FDA panel recommends approving Repatha, Praluent to lower cholesterol
In addition, “no incremental benefit of Vyotrin on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin [Zocor] has been established”, according to the statement.
FDA's decision follows a recommendation in December by one of its advisory committees that Merck should not be allowed to claim that Vytorin (ezetimibe/simvastatin) reduces the risk of heart attacks and strokes in patients with coronary heart disease, according to Reuters.
Related: Battle of the cholesterol drugs expected
Merck based its applications for the claims on the results of data from its 18,000-patient Improve-IT study. The study showed that Vytorin, a combination of the off-patent statin drug simvastatin with the active ingredient in Zetia, ezetimibe, beat simvastatin alone at cutting cardiovascular risks by 6.4%.
However, FDA reviewers noted that the reduction in risk was small and limited to certain types of patients, such as the elderly and diabetics.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
